Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1

Status

Completed 4Not yet recruiting 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Myasthenia Gravis 4

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Completed × rozanolixizumab × Clear all
NCT03971422 2025-12-24

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
200 enrolled 20 charts

Myasthenia Gravis

NCT05681715 2025-11-06

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

UCB Pharma

Phase 3 Completed
62 enrolled 11 charts

Myasthenia Gravis

NCT04650854 2025-04-18

A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
165 enrolled 21 charts

Myasthenia Gravis

NCT04124965 2023-09-05

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
71 enrolled 15 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡